On October 31, 2022 Theriva Biologics, Inc. (NYSE American: TOVX), ("Theriva" or the "Company"), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, reported that it will host a key opinion leader (KOL) webinar on Monday, November 7, 2022 at 11:00 a.m. ET to discuss the oncolytic virus landscape and the encouraging data that positions the Company’s novel oncolytic adenovirus (OV) platform at the forefront of development to address devastating cancers with high unmet need (Press release, Theriva Biologics, OCT 31, 2022, View Source [SID1234622640]). The discussion will also include recent findings from independent research highlighting the market opportunities for pancreatic ductal adenocarcinoma (PDAC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
VCN-01, Theriva Biologic’s lead clinical-stage drug candidate, is an intravenous, oncolytic adenovirus designed to break down the tumor stroma. Theriva’s upcoming Phase 2 clinical trial, VIRAGE, will evaluate VCN-01 in combination with standard-of-care chemotherapy gemcitabine/nab-paclitaxel in patients with PDAC.
The webinar will feature the KOLs Michael Aaron Morse, M.D., Professor of Medicine and Professor in the Department of Surgery in Medical Oncology at the Duke University School of Medicine, as well as Arsen Osipov, M.D., medical oncologist and clinical-translational investigator in the Gastrointestinal Disease Research Group and Pancreas Cancer Research Group of the Samuel Oschin Cancer Center at Cedars-Sinai. Dr. Morse is a pioneer in the use of immune therapies to treat various cancers, including gastrointestinal, breast, lung cancers and melanoma. Dr. Osipov focuses on the development of novel immunotherapy-based treatment strategies for gastrointestinal malignancies, with a focus on pancreatic cancer.
A live Q&A session will follow the formal discussion. To register for the event, please click here. An archived webcast will also be accessible in the "Events" section of the company’s website at www.therivabio.com.